Drug intelligence / Profile preview

eculizumab biosimilar Turgut

Development stage: Phase 1
Lead developer: Turgut Ardika
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TUR03 is a biosimilar monoclonal antibody developed as a proposed alternative to eculizumab (Soliris). It functions as a C5 inhibitor, targeting the complement component 5 (C5) protein to block terminal complement activation. This mechanism is relevant for diseases such as myasthenia gravis, where inhibition of the complement cascade can reduce immune-mediated damage. TUR03 is being developed by Turgut Ardika PTY LTD and has reached Phase 1 clinical trials in healthy volunteers for pharmacokinetic and safety comparison with Soliris. The drug is administered via intravenous injection and has not yet received regulatory approval in any country[1][2][3].

Other names: TUR-03TUR03TUR 03

Targets

Beyond the preview

Go deeper on eculizumab biosimilar Turgut.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eculizumab biosimilar Turgut.

Explore the full profile